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Abstract
Defects in ubiquitin E3 ligases are implicated in the
pathogenesis of several human diseases, including
cancer, because of their central role in the control of
diverse signaling pathways. RING E3 ligases promote
the ubiquitination of proteins that are essential to a
variety of cellular events. Identification of which ubiq-
uitin ligases specifically affect distinct cellular pro-
cesses is essential to the development of targeted
therapeutics for these diseases. Here we discuss two
novel RING E3 ligases, BCA2 and RNF11, that are
closely linked to human breast cancer. BCA2 E3 ligase
is coregulatedwith estrogen receptor andplays a role in
the regulation of epidermal growth factor receptor
(EGF-R) trafficking. RNF11 is a small RING E3 ligase
that affects transforming growth factorB and EGF-R
signaling and is overexpressed in invasive breast
cancers. These two proteins demonstrate the com-
plexity of RING E3 ligase interactions in breast cancer
and are potential targets for therapeutic interventions.
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Introduction
Protein homeostasis at the cellular level is delicately bal-
anced by de novo synthesis, posttranslational modification,
and degradation [1]. The majority (80%) of cellular proteins
is destroyed by the ubiquitin–proteasome system after
ubiquitin tagging [2]. The ubiquitin system is hierarchically
structured and confers specificity for protein substrates
through a multitude of E3 ubiquitin ligases. A few E1
ubiquitin-activating enzymes exist; however, at least 50 E2
ubiquitin-conjugating enzymes and about 500 E3 ubiq-
uitin ligases are present in the human genome [3–7]. E2
ubiquitin-conjugating enzymes are characterized by a con-
served core sequence and by the ability to bind toE3 ligases.
E2 ligases are therefore believed to have functional redun-
dancy [7]. E3 ubiquitin ligases are currently grouped into
two major categories: HECT-type and adaptor-type. The
latter can contain a RING finger, a U-box, or a PHD domain
[5,8–12]. RING E3 ligases mediate the direct transfer of
E2-bound ubiquitin to substrates without thioester bond
formation [11]. This is in contrast to HECT E3 ligases, which
actively take up E2-bound ubiquitin by forming thioester link-
ages and then transferring ubiquitin to substrates.
Many of the knownE3 ligases play a role in various diseases,
including breast cancer development and progression. Among
the first RING proteins to be associated with ubiquitination
and cancer were the multisubunit complex E3 ligases ROC1
and APC11 [9,13]. The small RING finger protein ROC1 is
an essential component of the multisubunit complex Skp1/
cullin-1/F-box protein (SCF) E3 ligase [9]. This family of RING
finger proteins interacts with cullins, creating a large number of
multisubunit E3 Ub ligases of varying specificity [13]. SCF-type
complexes ubiquitinate a broad range of substrates involved
in cell signaling, cell cycle progression, signal transduction,
and transcription [14]. In primary breast cancers, p27 levels
are reduced by the SCF complex, leading to poor prognosis
[5,14–16]. APC11 is a core catalytic subunit of the anaphase-
promoting complex, which allows exit of cells from mitosis by
destroying B-type cyclins complexed with Cdc2, resulting in
the loss of Cdc2 kinase activity [17].
Closely associated with breast cancer are variousmonomeric
RING finger E3 ligases, including Mdm2, Efp, c-Cbl, BRCA1/
BARD1, COP1, and BCA2 [5,9,18,19]. Monomeric RING finger
E3 ligases, unlike those participating in the SCF complex, have
a substrate-binding domain and are capable of substrate ubiq-
uitination and autoubiquitination. COP1, Mdm2, and BRCA1/
BARD1 have a common substrate, namely, p53 [20,21].
COP1 has been found to be significantly overexpressed
in 81% of breast carcinomas, and p53 is decreased in tu-
mors expressing COP1 [19]. Germline mutations in the RING
finger of BRCA1 predispose women to early-onset breast
tumors [5], accounting for approximately 5% of breast cancers.
The BRCA1-associated RING domain protein BARD1 acts with
BRCA1 in double-strand break repair and ubiquitination.
BRCA1 ubiquitin ligase activity is enhanced when it is di-
merized with BRCA1-associated RING domain (BARD1), and
it has been implicated as a mediator of apoptosis by binding
to and stabilizing p53 [20,22]. Although COP1 seems to be
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a negative—and BRCA1/BARD1 seems to be a positive—
regulator of p53 in breast cancer, the role of Mdm2 is less
clear. Mdm2 was found to be an independent negative
prognostic marker by studying protein expressions in a large
number of microarrayed breast cancer cases [23]. How-
ever, Mdm2 expression in this tumor collection was not cor-
related to clinicopathological parameters. In a study that
subclassified breast cancers, Mdm2 overexpression was
associated with favorable prognostic markers: absence of
lymph node involvement, low-grade nuclear atypia, and
increased levels of estrogen receptor a protein [23,24]. Efp
is an estrogen-inducible RING finger E3 ligase that ubiq-
uitinates the 14-3-3j protein. 14-3-3j is a p53-regulated
inhibitor of G2/M progression and has been shown to have
tumor-suppressor function in breast cancer [25,26]. A survey
of 151 breast cancers confirmed that Efp immunoreactivity is
positively associated with lymph node status or estrogen
receptor a status, and is negatively correlated with histologic
grade or 14-3-3j immunoreactivity. Efp immunoreactivity
was significantly correlated with poor prognosis [27]. c-Cbl
is an E3 ligase with a RING finger and an SH2 domain. It
recognizes phosphorylated tyrosine residues in receptor
tyrosine kinases through its SH2 domain, and it negatively
regulates signaling by facilitating receptor ubiquitination
[28–32]. In particular, c-Cbl acts as an E3 ligase, bringing
together tyrosine-phosphorylated receptors and E2 ubiquitin-
conjugating enzymes. It thus induces the ubiquitination of
activated tyrosine kinase receptors, including epidermal
growth factor receptor (EGF-R) and platelet-derived growth
factor receptor (PDGF-R). c-Cbl–dependent ubiquitination
was shown to be important for early endosome to late endo-
some/lysosome sorting step during EGF-R turnover and,
thus, was established as amajor endogenous ubiquitin ligase
responsible for EGF-R degradation [28,32]. Cbl has also
been described as a suppressor of theHER2/Neu oncogene,
which belongs to the EGF-R superfamily [29]. Overexpres-
sion of EGF-R, HER2/Neu, and EGF-R family heterodimer
signaling is a major contributor to uncontrolled proliferation in
many malignant diseases, including breast cancer [30]. The
HER2 antibody trastuzumab (Herceptin; Genentech, San
Francisco, CA) has been shown to direct HER2 to c-Cbl–
regulated degradation, suggesting that mechanisms under-
lying the efficacy of trastuzumab immunotherapy might, in
part, be due to EGF-induced degradation of HER2 by c-Cbl–
mediated ubiquitination [31].
The following sections will focus on the role of two novel
breast cancer–associated RING finger E3 ligases: the small
RING finger protein RNF11 and the monomeric RING-H2
ubiquitin E3 ligase BCA2. Their potential usefulness as
prognostic markers or therapeutic targets is also discussed.
RNF11 in Transforming Growth Factor (TGF)B–
and EGF-R–Mediated Signaling
RNF11 encodes a RING-H2 domain and a PY motif, both of
which mediate protein–protein interactions. In particular,
the PPPPY sequence of the RNF11 PY motif is identical
to that of Smad7, which has been shown to bind to WW
domains of Smurf2—an E3 ubiquitin ligase that mediates
the ubiquitination and degradation of the TGF receptor com-
plex (Figure 1) [14,15].
TGFb is associated with both normal mammary gland
development and breast carcinogenesis [33–35]. A dichoto-
mous role for TGFb in breast cancer as both a tumor
suppressor in early-stage disease and as a tumor promoter
in advanced disease has been described [36]. Many breast
cancer cell lines show an increased expression of TGFb but
are refractory to TGFb-induced cell cycle arrest. In addition, in
many cancers, tumor cells lose responsiveness to TGFb,
leading to the idea that the disruption of this pathway may
be an important factor in the development of cancer [37,38].
However, deletions of TbRII or Smads only represent a
small fraction of cancers that are insensitive to TGFb. Thus,
there must be other uncharacterized proteins, such as
RNF11, that contribute to the deregulation of the TGFb
signaling pathway and the accompanying TGFb insensitivity
evident in cancer cells.
Along those lines, we have found that RNF11 is capable of
binding Smurf proteins that are involved in the TGFb pathway
[39–41]. Through its PY motif, RNF11 binds to the HECT-
type E3 ligase Smurf2, making it a potential regulator of
TGFb signaling. RNF11 also competes with Smad7 binding
to Smurf2, thereby disrupting the Smurf2/Smad7 complex
(Figure 1) [42,43]. This prevents the negative effects of the
Smurf2/Smad7 complex on TGFb signaling and acts to
restore TGFb sensitivity to cells that have lost their respon-
siveness; overexpression of RNF11 increases the stability
of the TGFb receptor [41]. The interaction of RNF11 and
Smurf2 could be crucial because it restores TGF signaling
and because RNF11 could have multiple functions similar to
those of Smad proteins. Perhaps RNF11 blocks some of the
inhibitory effects of Smad7 on TGF signaling on cell prolifer-
ation and apoptosis, but leaves intact the positive effects of
this pathway on malignant progression.
EGF-R is considered to be one of the main proteins that
are elevated in breast cancers [44]. A strong correlation has
been found between the presence of high levels of EGF-R
in breast tumors and the aggressive potential of the tumor.
EGF-R contains multiple phosphorylated residues, each of
which directly interacts with specific domains in downstream
Figure 1. Model of RNF11 interactions in the TGF receptor signaling path-
way. RNF11 acts against the degradation of the TGF receptor, enhancing its
tumor-suppressor effects on breast cancer.
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signaling proteins. Under normal conditions, there are mul-
tiple mechanisms in the cell that act to tightly regulate these
activities. These include positive regulation by growth factors,
in addition to negative regulation of the receptor or of down-
stream signaling pathways through the action of phospha-
tases or other regulators of signaling pathways. Recently,
ubiquitin ligases have been identified as such negative reg-
ulators. They primarily act following ligand stimulation, and
internalized receptors are subject to two distinct fates: re-
cycling back to the plasma membrane or degradation by
lysosomal and proteosomal pathways.
Growing evidence indicates that ubiquitination of EGF-R
and other receptor tyrosine kinase (RTKs) is critical for their
lysosomal degradation through ubiquitin-dependent protein
sorting, which retains RTKs in late endosomes and subse-
quently targets these receptors to intralumenal vesicles and
lysosomal degradation [32,45–48]. RTKs can also be multi-
monoubiquitinated, and monoubiquitination of EGF-R specif-
ically is sufficient for its internalization and degradation [49].
Ubiquitinated receptors may be selectively recognized by
proteins of the endocytic pathway that contain a ubiquitin-
interacting motif, such as Epsin, EPS-15, Hrs, and STAM, and
many other proteins [49,50]. We found that RNF11 associates
withEPS-15andAMSH,which is themolecule associatedwith
the SH3 domain of STAM (AMSH). AMSH is an endosome-
associated ubiquitin isopeptidase, and we have reported that
its degradation is enhanced by RNF11 protein.
EPS-15 plays a major role in the clathrin-mediated inter-
nalization of EGF-R [51]. On activation, EGF-R phosphor-
ylates EPS-15 at tyrosine 305. In an elaborate series of
events, a multiprotein complex that includes hepatocyte
growth factor– regulated tyrosine kinase substrate (Hrs)
and STAM binds to EGF-R, causing its internalization and
degradation by lysosomal proteolysis [52,53]. This process
requires an activated EGF-R and keeps EGF-R signaling in
check. In contrast, EGF-R internalization is inhibited by
AMSH protein. AMSH is a deubiquitinating enzyme that
deubiquitinates ubiquitinated EGF-R and prevents the for-
mation of the complex necessary for EGF-R internalization,
which in turn prolongs EGF-R activation and promotes cellu-
lar proliferation. We have shown that RNF11 binds to AMSH
and, in the presence of the E3 ligase Smurf2, promotes the
ubiquitination and degradation of the AMSH protein [40].
In addition, it has been shown that RNF11 can bind directly
to EPS-15. In order for EPS-15 to form a complex with Hrs
and STAM, it must be monoubiquitinated following phos-
phorylation by EGF-R. Thus, it may be that, by its interaction
with E2 and E3 ligases, RNF11 can mediate the mono-
ubiquitination of EPS-15. This suggests that RNF11 could
promote the internalization and degradation of EGF-R by
two distinct protein–protein interactions by sequestering
AMSH away from STAM and/or by mediating the mono-
ubiquitination of EPS-15.
BCA2 E3 Ligase and Its Partners in Breast Cancer
BCA2 (synonymous to T3A12/ZNF364/Rabring7) has been
identified as a novel breast cancer–associated gene by
subtractive hybridization cloning of cDNA derived from
matched normal and malignant breast cell RNA [54]. BCA2
has a close relative (RNF126) that shares 46% overall amino
acid identity and 75% identity in RING domains. Both genes
contain nine exons, encoding consensus AKT/14-3-3–bind-
ing sites, as well as zinc finger and RING finger domains
(Figure 2A). A comparison of the RNF126 amino acid se-
quence with translated nucleotide sequences revealed
probable homologues of BCA2 in vertebrate species, includ-
ing humans, mice, birds, amphibians, and fish. This suggests
that RNF126 might have a similar function as BCA2.
RING domain proteins have multiple motifs and domains
that allow them to interact with multiple partner proteins.
Others have shown that BCA2 is a target protein of Rab7
(a member of the Rab family of small G proteins) and that
BCA2 also interacts with ALG2 [18,55,56]. Moreover, it was
found that BCA2 significantly inhibited EGF degradation [56].
We have confirmed this interaction between the human
Rabring7/BCA2 protein and the human Rab7 by using recom-
binant BCA2 (Xpress-tagged) and GST–Rab7 (Figure 3).
Recombinant mutant AKT BCA2 protein does not bind to
Rab7, raising the possibility that BCA2 phosphorylation by
AKT [57] is essential to BCA2/Rab7 interaction. That inter-
action could affect receptor internalization and vesicle traf-
ficking in the cytoplasm, separate from the E3 ligase function
of BCA2 in the nucleus [18].
Two partner proteins for RNF126, Traf6, and BAT3/Scythe
have been discovered in high-throughput screening [58,59].
Although few other partners for either RNF126 or BCA2 have
been identified, both proteins interact with one or more
apoptosis-related proteins. Both BCA2 and RNF126 may
interact with Scythe, and BCA2 interacts with ALG2. It may
be that, in addition to or as a consequence of preserving gene
structure, functional domains, and motifs, the general func-
tions of these proteins have also been conserved through-
out evolution.
Other potential binding motifs/partners can be de-
duced from the functional domains of BCA2 and RNF126
(Figure 2A), which include an AKT phosphorylation site within
a potential 14-3-3–binding domain. 14-3-3 Molecules are a
family of proteins that bind phosphorylated serine/threonine
residues within a consensus-binding sequence. Several
members of this gene family are downregulated in breast
cancer, such as 14-3-3j, which is a substrate of the E3 ligase
Efp (seeRefs. [18,25–27,57]). Both BCA2 andRNF126 have
E3 ligase activity that could be affected by phosphorylation
of their AKT sites (Figure 4) [18]. Those sites are located
within 14-3-3–binding domains in exon 4 of BCA2 and
RNF126 (Figure 2A). Mutation of the AKTsite of BCA2, unlike
RING mutation, does not lead to complete loss of E3 ligase
activity [18], suggesting that phosphorylation could con-
tribute to BCA2 and perhaps RNF126 E3 ligase function in
breast cancer.
By employingmultitumor tissuemicroarray technology, we
found that normal breast, colon, and head and neck tumors
lack detectable BCA2 expression (Figure 5A) [60]. Twenty of
20 breast cancers and 15 of 15 prostate cancers strongly
expressed BCA2 (Figure 5B) [60]. Sixty percent of 17 renal
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cancers had strong BCA2 staining, and none of the clear cell
renal tumors had detectable BCA2. Lower levels of BCA2
staining were seen in 57% of 16 colon cancers, in 65% of
22 pancreatic tumors, and in 73% of 17 bladder cancers.
Weak expression of BCA2 was seen in 4 of 7 lung tumors and
in 6 of 11 head and neck tumors.
A second larger tumor tissue microarray study examined
BCA2 expression in 945 invasive breast cancers [18]. Com-
parison with patient data revealed that BCA2 expression
correlates with clinical variables such as lymph node status,
regional recurrence, and estrogen receptor expression pat-
tern [18,60]. Although BCA2 expression in the entire cohort
did not correlate with overall survival, a subset of patients
with regional recurrence history revealed that a higher BCA2
is linked with a significant 5-year survival benefit and that a
low BCA2 is linked with lymph node metastasis. The corre-
lation of BCA2 expression with estrogen receptor positivity
indicates that BCA2 and estrogen receptor might be coregu-
Figure 3. BCA2 binds to Rab7. The GST–Rab7 fusion protein was incubated
with Xpress-tagged recombinant BCA2 bacterial product at increasing con-
centrations of GST–Rab7.
Figure 4. BCA2 and RNF126 E3 ligase activity. Autoubiquitination of
recombinant BCA2 and RNF126. In vitro ubiquitination assays were per-
formed with (+) and without () the E2-conjugating enzyme UbcH5b in the
presence of ubiquitin. Shown is an anti-ubiquitin Western blot analysis of the
reaction products visualized by chemiluminescence. High-molecular-weight
products indicative of polyubiquitination are seen only when E2 is present in
the reaction.
Figure 2.Modular domains and binding sites in RNF126 and BCA2. (A) Schematic diagram of RNF126 and BCA2 protein sequences with originating exonsmarked in
color, and with consensus zinc finger, AKT phosphorylation, and RING domains and sites indicated. Exons 4 and 9 bear unique codons that extend the length of
RNF126 to 326 amino acids, 22 amino acids more than BCA2. Exon 4 of both RNF126 and BCA2 encodes a consensus AKT/14-3-3–binding site. (B) Detailed
alignment of RNF126 and BCA2 domains and sites, as indicated with amino acid sequence locations that are numbered, with structurally important residues in purple
or green and with potential phosphorylation sites marked in red. The RNF126 sequence has threonine residues, rather than serine residues, seen in BCA2 as likely
sites of phosphorylation. (C) Amino acid regions unique to RNF126, including the serine tract and consensus SH3-binding sequence (Prosite).
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lated and cross-talked at the transcriptional level, perhaps
in the nucleus.
Conclusions
When RING finger proteins were discovered, their role was
recognizedmainly in protein–protein interactions and protein
dimerization [9]. As evidence evolved, their crucial function in
mediating the transfer of ubiquitin to heterologous substrates
as well as to themselves (autoubiquitination) and their crucial
function as substrates with key roles in cell signaling and sur-
vival pathways emerged. RING E3 ligases have now become
the subject of intense studies for their roles in disease and as
potential therapeutic targets [5,6,9]. Several cancer-specific
Figure 5. Expression of BCA2 protein in normal and tumor tissues. One hundred twenty-five tumor tissues and adjacent normal tissues from the same patient were
assembled onto a tissue microarray slide, fixed, and probed for BCA2 expression by immunoperoxidase staining (positive reaction, brown). (A) The top panel
shows representative cores (0.6 mm) of normal breast, colon and head and neck tissues stained for BCA2 protein expression (original magnification, 4). (B) The
bottom panel shows strong nuclear and cytoplasmic expression of BCA2 in breast, prostate, and papillary renal cell cancers, but very weak staining in clear cell
renal, colon, and head and neck carcinomas (original magnification, 40).
Figure 6. Model of BCA2 and Rab7 interactions of intracellular vesicle trafficking in breast cancer. Receptor-mediated endocytosis internalizes activated EGF-R
complexes and transports them to the early endosome for sorting. Rab GTPases regulate vesicle fusion events during this process. BCA2 plays crucial roles as a
Rab7 target protein in vesicle traffic up to late endosome/lysosome and lysosome biogenesis.
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oncogenes code for ubiquitin ligases and/or their subunits.
Interestingly, breast cancer, in particular, seems to be as-
sociated with the aberrant expression of several RING E3
ligases and their substrates.
All RINGE3 ligases, including BCA2, contain a consensus
protein sequence that would complex two zinc ions in the
expressed protein (Figure 2A). This domain is likely essential
to the ligase activity of all RING E3 ligases [5,18]. This
dependence on the RING domain is demonstrated by the
loss of E3 ligase activity in mutant RING proteins [18].
The crucial role of the RING-H2 finger and its zinc-
complexing structure for BCA2, RNF126, and other RING E3
ligases is underscored by the fact that the zinc-ejecting com-
pound disulfiram is able to inhibit BCA2 autoubiquitination
[18,60,61]. Abrogation of E3 ligase activity by the zinc-ejecting
compound has important implications for the therapeutic in-
tervention of RING finger E3 ligase–mediated diseases. Di-
sulfiram (Antabuse; Odyssey Pharmaceuticals, Inc., East
Hanover, NJ) is in clinical use for the treatment of alcoholism
owing to its ability to inhibit alcohol dehydrogenase (ADH) and
has thus proven tolerability in humans [5,18]. If analogs with
retained or even enhanced zinc-ejecting capabilities but with-
out ADH inhibition could be developed, they might prove
valuable for the treatment for cancers with imbalances
of RING finger ligase signatures, such as breast cancer [5].
The biology of BCA2 demonstrates how E3 ligases can
havemultiple cellular functions. In the cytoplasm, BCA2binds
to Rab7 and plays a role in the lysosomal degradation of
RTKs. In the nucleus, BCA2 augments ubiquitin-mediated
degradation of target proteins destined for proteasomal deg-
radation (Figure 6). The flexibility of RING E3 ligases is
enhanced by the regulation by RTK signaling (e.g., BCA2
is regulated by AKT-mediated phosphorylation and auto-
ubiquitination). These complex mechanisms need to be con-
sidered when designing therapeutic strategies. Rather than
inhibiting ligase activity alone, a combined approach of E3
ligase inhibition and AKT inhibition might be most effective.
Modulating E3 ligase activity can lead to tumor growth
inhibition, as exemplified by geldanamycin analogs that in-
duce CHIP activity or by zinc-ejecting agents that can inhibit
RING finger ubiquitin ligases such as BCA2. Thus, the dis-
covery and development of truly specific E3 ligase inhibitors
are likely to be highly rewarding and could provide targeted
therapies for many tumor types.
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